Why GLP-1 Makers Reported 3% Hair Loss When the Real Number Is 70%

Between 2021 and 2024, more than 1,000 women filed formal complaints with the FDA describing significant hair loss on GLP-1 medications, and by January 2024 those reports were numerous enough that regulators opened a formal investigation into GLP-1-associated hair loss. It is now 2026, and not a single prescribing label for Ozempic, Wegovy, Mounjaro, or Zepbound has been updated to reflect what those reports described.

The investigation into the disclosure gap started with a straightforward question: if GLP-1 medications were causing hair loss at the rate women were reporting, why did the clinical trial data say something so different?

The answer was in how those trials were designed. The studies that produced the 3% figure ran for 16 to 68 weeks and tracked hair loss through self-reported adverse events, which meant a patient had to notice the shedding, decide to mention it, and have that report formally recorded. What that methodology cannot capture is the hair loss that starts in month four or five, well after many shorter trials had already ended, and it cannot capture the women who assumed it was stress, or aging, or something else entirely.

However, in 2025 a systematic review of more than 84,000 GLP-1 users found a hair loss risk 3.4 times higher than in patients not on these medications, and separate studies of women specifically put the number experiencing significant shedding closer to 70%. A University of British Columbia analysis of nearly 2,000 patients found that women on semaglutide are more than twice as likely to experience hair loss as men on the same medication, a gender-specific disparity the original trials were never designed to detect.

When women began reporting hair loss to their doctors, the medical system reached for what it knew: biotin for nutritional support, minoxidil to stimulate growth, Nutrafol as the premium supplement option. These were the established treatments for hair loss, so they were applied to this one.

That is where the second failure begins.

Think of it this way. If you went to the emergency room with a burn on your hand and the doctor handed you antihistamine cream and told you to apply it twice daily, you would say: this is for allergies, I have a burn, why would allergy medication help a burn? You would be right, because the treatment for a burn and the treatment for an allergy are completely different, and using one for the other does not just fail, it wastes the time you needed to spend treating the actual problem.

Every product in the standard hair loss toolkit, from biotin to Nutrafol to minoxidil to rosemary oil, was formulated for androgenetic alopecia, which is the medical term for hormonal pattern baldness. Androgenetic alopecia is caused by a hormone called DHT gradually shrinking follicles over years, and the entire $5.6 billion hair loss supplement industry was built to block it.

GLP-1 hair loss has nothing to do with DHT. It is not hormonal. It is metabolic, and that distinction changes everything about what will work and what will not.

GLP-1 medications do not cause hair loss through a single pathway. They cause it through four simultaneously, and no product on the market was built to address all four at once.

The first is metabolic shutdown: Rapid weight loss signals your body that resources are scarce, and it responds by pulling energy away from non-essential functions, growing hair being one of them. Follicles get pushed prematurely into the resting phase, a process called telogen effluvium, and shedding typically begins around months three or four.

The second is nutritional starvation: GLP-1 medications suppress appetite by 30 to 50 percent, so the body is taking in far less of the protein, iron, and zinc follicles need to build hair. And because these medications also slow gastric emptying by 40 to 70 percent, the supplements most women turn to absorb at a fraction of their labeled dose. The medication causing the hair loss is simultaneously undermining the most common attempt to fix it.

The third is oxidative stress: Rapid fat mobilization floods the body with free radicals, which are unstable molecules that damage cells at the level of their energy-producing engines, and hair follicles are particularly vulnerable because of how metabolically active they are.

The fourth, and the one that makes waiting increasingly costly, is stem cell exhaustion: Every follicle has a small reservoir of stem cells that initiate each new growth cycle, and sustained metabolic stress depletes it over time. This force does not stabilize on its own. It gets worse the longer it goes unaddressed, which is why the three to seven month window matters.

Biotin addresses the second force, partially. Nutrafol addresses part of the second force while directing the rest of its formula toward blocking DHT, which is not one of the four forces. Minoxidil stimulates growth but addresses none of them, simply overriding the resting phase while the underlying drivers continue unchecked.

You were not fighting a single-front battle. You were fighting four, and everything you tried was designed for a completely different war, delivered through a route your medication had already compromised.

There are two routes to the hair follicle. The first is oral, and the problem with it for GLP-1 users was already covered: gastric emptying slows by 40 to 70 percent, and supplements degrade in stomach acid before they can be absorbed properly.

The second route is topical, and this is the one nobody mentions. Studies consistently show that 98 percent of active ingredients applied to the scalp’s surface never penetrate the skin barrier to reach the follicle. They sit on the skin. The follicle, where the actual problem lives, receives almost none of what was applied.

Both routes fail. Which means the question is not only which ingredients to use, but how to get them past the barrier that has been blocking them.

The clinical answer to that question has existed since 2013. A study published in the International Journal of Trichology compared two groups of patients with hair loss: one using a standard topical solution applied to the scalp, and one using the same solution delivered through microneedling, a process where fine needles create temporary micro-channels through the skin barrier, allowing active ingredients to pass directly to the dermal papilla, which is the tissue that feeds the follicle. The topical-only group saw a mean hair count increase of 22.2. The microneedling group saw 91.4. Four times the result, using identical ingredients, with the only variable being delivery.

The implication is not subtle. If 98 percent of what you apply to the scalp never reaches the follicle, the delivery mechanism may matter more than any ingredient on the label.

What this investigation found, at the end of the data, is that no product had been designed with GLP-1 hair loss specifically in mind. Every micro-infusion system on the market was formulated around DHT inhibition for hormonal pattern baldness. Every oral supplement was built for general nutritional deficiency without accounting for the gastric emptying problem. Nothing addressed metabolic telogen effluvium through all four forces, with ingredients at clinical concentrations, delivered through a route the medication could not compromise.

Genology was built to fill that gap.

The formula contains 26 clinical ingredients selected specifically for their evidence against the four forces of metabolic hair loss: apple stem cells for stem cell exhaustion, Vitamin C and Ferulic Acid for oxidative stress, GHK-Cu and Capixyl for follicle rescue and anchoring, AnaGain for growth phase reactivation. There are no DHT blockers in the formula, not because they were overlooked, but because DHT is not driving this problem. Every competitor includes them because every competitor was built for hormonal hair loss. Genology deliberately excludes them, because including a DHT blocker in a formula for metabolic hair loss is the equivalent of adding allergy medication to a burn treatment.

Apple stem cells

For stem cell exhaustion.

Vitamin C + Ferulic Acid

For oxidative stress.

GHK-Cu + Capixyl

For follicle rescue and anchoring.

AnaGain

For growth phase reactivation.

Delivery is through a 0.5mm 24-karat gold microneedle device that creates temporary micro-channels through the scalp barrier, reaching the dermal papilla directly. The protocol is two minutes, three times a week.

1

Part and apply

Apply serum directly to a clean scalp part line.

2

Stamp

Create temporary micro-channels through the scalp barrier.

3

Absorb

Continue your normal routine while the formula absorbs.

Most women reading this have already spent hundreds of dollars on products that did not work, and that history makes spending again harder, not easier. It is a rational response to repeated disappointment.

The 120-day Hair Recovery Guarantee exists for exactly that reason. One hundred and twenty days is one complete hair cycle, which is the biologically honest minimum for measuring whether a treatment is actually working. If you use Genology for a full hair cycle and do not see meaningful improvement in shedding and regrowth, you get your money back, including on empty bottles. No forms. No conditions.

It is called the Hair Recovery Guarantee deliberately, because recovery is the expected outcome, not the exceptional one.

GLP-1 hair loss is not identical for every woman. How long you have been shedding, which medication you are on, and where you are in the recovery window all affect what the data recommends for your specific situation.

A sixty-second assessment maps your situation to the research. It is free, it takes less than a minute, and it will tell you exactly where you stand.